A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants with Duchenne Muscular Dystrophy (DMD)

Trial Identifier: 0367-CL-0102
Sponsor: Astellas Pharma Inc.
Start Date: February 2021
Primary Completion Date: September 2022
Study Completion Date: September 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, CA Sacramento, CA, United States of America, 95817
United States of America, KS Kansas city, KS, United States of America, 66160
United States of America, MA Worcester, MA, United States of America, 01655
United States of America, MD Baltimore, MD, United States of America, 21201
United States of America, VA Richmond, VA, United States of America, 23219